Teva UK launches generic Ibandronic Acid for osteporosis

Teva UK has introduced Ibandronic Acid, a new generic treatment for osteoporosis among postmenopausal women at increased risk of fracture.

The new product is an off-label equivalent of Roche's branded therapy Bonviva and is being released in a number of pack sizes, all under the company's award-winning Teva 360 livery.

Administered via 150mg film-coated tablets, the drug has been demonstrated in clinical trials to help osteoporosis patients benefit from a reduced risk of suffering vertebral fractures.

Kim Innes, commercial director at Teva, said: "We've now launched 21 products this year, including ten on day one of patent expiry, in a variety of strengths and pack sizes."

This comes after the company introduced Benzydamine Oromucosal spray, a locally-acting analgesic and anti-inflammatory treatment for the throat and mouth, earlier this month.

Based on Meda Pharmaceuticals' branded product Difflam, it is particularly useful in relieving pain in traumatic conditions, such as following a tonsillectomy, dental surgery or the use of a naso-gastric tube.